References
Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SD et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-012-2549-x.
Hattori Y, Ubara Y, Sumida K, Hiramatsu R, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012;19:37–40.
Inoue D, Arima H, Kawanami C, Takiuchi Y, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195–1197.
Magro-Checa C, Navas-Parejo Casado A, Borrego-García E, Raya-Álvarez E, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011;18:235–239.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cañas-Ventura, A., Rodríguez, E., Andreu, M. et al. Tocilizumab in Amyloidosis-Associated Kidney Disease Secondary to Inflammatory Bowel Diseases. Dig Dis Sci 58, 2736–2737 (2013). https://doi.org/10.1007/s10620-013-2776-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2776-9